Similarly, the model predicts greater sensitivity (lower IC50) to isocitrate dehydrogenase (IDH) inhibitors in patients with mutant IDH (mIDH) gliomas compared to wild-type IDH (wtIDH) cases (Figure 1(BII)). The gene discussed is IDH1; the disease is central nervous system cancer.